Wall Street analysts expect DaVita to report Q2 2026 consensus revenue of $3.49 billion and earnings per share of $3.88, with the current stock price of $240.09 trading well above the average analyst price target of $216.50. The primary story for investors is the sustainability of patient treatment volume and revenue per treatment, which are the core drivers of the company's recent organic growth. This report follows a significant upward revision in management's full-year 2026 EPS guidance to a range of $14.10–$15.20 after strong first-quarter margins. Market participants are closely watching to see if productivity gains and a favorable payer mix can continue to offset persistent labor costs and inflationary pressures. Total shareholder returns have been robust leading into this print, supported by aggressive share repurchases and improved operational efficiency across DaVita's dialysis center network.